AstraZeneca stock
Price history
+2.27% over the period1 year: from 13,592.00 GBp (November 17, 2025) to 13,900.00 GBp (November 17, 2026), +2.27%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | 13,900.00 GBp |
| October 30, 2026 | 13,960.00 GBp |
| September 30, 2026 | 12,280.00 GBp |
| August 28, 2026 | 11,970.00 GBp |
| July 31, 2026 | 12,632.00 GBp |
| June 30, 2026 | 14,100.00 GBp |
| May 29, 2026 | 13,802.00 GBp |
| April 30, 2026 | 13,948.00 GBp |
| March 31, 2026 | 14,690.00 GBp |
| February 27, 2026 | 15,542.00 GBp |
| January 30, 2026 | 13,600.00 GBp |
| December 31, 2025 | 13,790.00 GBp |
| November 28, 2025 | 13,974.00 GBp |
| November 17, 2025 | 13,592.00 GBp |
At a glance
The company
Discovers, develops, manufactures and commercializes prescription medicines in oncology, cardiovascular, renal, metabolism, respiratory and rare diseases
Latest results
Quarter to September 30, 2026 · EPS $2.79 (estimate $2.59)
TickerLandia's take on AstraZeneca
- Pricier than similar companies: trailing 12-month P/E 27 vs 22 (+24%) in a group of 10.
- Strong point: Market momentum (58/100 in its group). Weak point: Earnings stability (32/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−12.27% from the 52-week high
Analysts · 24 analysts
Average target16,344.10 GBp+18.42% vs. price
Buy 19 · Hold 5 · Sell 0 · Buy
TickerLandia Fingerprint: AstraZeneca
Compared with similar companies: low earnings stability, low financial strength, and high risk.
Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Priceaverage53
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 11.5 46 P/E (trailing 12 months) 26.6 59 Price/book 5.64 56 Price/sales 3.49 46 Forward P/E 16.5 56 Profitabilityaverage56
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 81.8% 90 Net margin 17.7% 62 ROE 22.6% 56 ROA 8.6% 38 Operating margin 25.8% 34 Earnings stabilitylow32
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 8.4% 10 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 54 Growthaverage56
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +9.82% 66 Revenue growth (year over year) +6.70% 38 Earnings growth (year over year) +23.50% 65 Financial strengthlow35
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.21 38 Current ratio 1.01 18 Interest coverage 10.5 30 Debt/equitycounts in reverse: lower means more financial strength 0.66 52 Dividendaverage43
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 34 years 76 Dividend yield 1.7% 23 Payout ratio 45.4% 31 Market momentumaverage58
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +18.46% 93 Relative strength (6 months) −4.47% 49 1-year return +1.55% 36 Distance from 200-day average +2.70% 53 Riskhigh61
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 26.3% 57 Volatility (60 days) 27.0% 50 Beta (1 year) 1.06 75
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
AstraZeneca is pricier than similar companies
AstraZeneca's P/E (trailing 12 months): 26.6, +24% against the median of a group of 10 similar companies (21.5).
Compared with 10 similar companies
| Metric | AstraZeneca | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 26.6 | High | |
| Forward P/E | 16.5 | High | |
| Operating margin | 25.8% | Middle | |
| ROE | 22.6% | Middle | |
| Debt/equity | 0.66 | Middle |
Grey band: the middle half of the group; tick: the median; dot: AstraZeneca. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$16.21B
Latest quarter · Q3 2026
Net income
$3.12B
Latest quarter · Q3 2026
Quarterly net margin
19.2%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- £217.66B
- P/E
- 26.6
- EPS
- 527.00 GBp
- Volume
- 2.29M
- Daily trading
- €398.22M
- Dividend yield
- 1.73%
- Last ex-dividend on August 6, 2026
How AstraZeneca is changing
All resultsRevenue grew 17.2% a year on average over the last 5 years
Operating margin rose from 8.5% to 23.4%
Profits turn into cash: free cash flow equal to 132% of net income
Returns
AstraZeneca returns with dividends
£1,000 invested in AstraZeneca 5 years ago, on November 17, 2021, would be worth £1,797 today with dividends reinvested: +79.70% in total, +12.44% per year. On price alone it would be £1,618 (+61.82%).
| Period | AstraZeneca | FTSE 100 | £1,000 becomes |
|---|---|---|---|
| 1 month | +12.10% | +0.38% | £1,121 |
| 6 months | +1.25% | +5.98% | £1,012 |
| Year to date | +0.80% | +8.80% | £1,008 |
| 1 year | +4.03% | +11.68% | £1,040 |
| 3 years | +43.85% | +43.99% | £1,439 |
| 5 years | +79.70% | +48.20% | £1,797 |
| 10 years | +324.29% | +59.02% | £4,243 |
Over the last 6 months it has done better than 18% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. FTSE 100: price only. Calculate your investment
The chart in detail
AstraZeneca: technical analysis
AstraZeneca shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 11.2% below its all-time closing high (15,542.00 GBp, February 27, 2026).
- Trend
- No clear trend
- RSI (14 sessions)
- 61
- Between 30 and 70
- vs 200-session average
- +2.70%
Support and resistance
Price areas where AstraZeneca has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance15,462.18 GBp+12.03%2 touches, last on April 10, 2026
- Resistance14,212.67 GBp+2.98%3 touches, last on November 5, 2026
- Resistance13,913.97 GBp+0.81%3 touches, last on June 8, 2026
- Last price13,802.00 GBp
- Support13,465.00 GBp−2.44%2 touches, last on March 23, 2026
- Support13,264.33 GBp−3.90%6 touches, last on July 29, 2026
- Support12,714.00 GBp−7.88%2 touches, last on September 29, 2026
Volatility and risk
Over the last year it has moved roughly in line with the FTSE 100.
- Beta (1 year) vs FTSE 100
- 1.06
- Volatility (60 sessions, annualised)
- 27.0%
- Largest fall in the last year
- −26.26%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
AstraZeneca: seasonality
Average monthly price change over 34 years
Over the last 34 years, the strongest month for AstraZeneca has been March: +2.65% on average, positive in 19 years out of 33. The weakest has been February: −0.62% on average, positive in 13 years out of 33. November, the current month, has been positive in 16 years out of 33 (+0.76% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.06% | −0.70% | 15 of 33 |
| February | −0.62% | −1.14% | 13 of 33 |
| March | +2.65% | +1.92% | 19 of 33 |
| April | +2.19% | +2.32% | 21 of 33 |
| May | +0.75% | +0.73% | 18 of 33 |
| June | +1.91% | +0.90% | 18 of 34 |
| July | +1.21% | +1.41% | 22 of 34 |
| August | +0.80% | −0.46% | 16 of 34 |
| September | −0.03% | +0.94% | 21 of 34 |
| October | +1.58% | +1.54% | 19 of 34 |
| November | +0.76% | −0.57% | 16 of 33 |
| December | +0.59% | +0.47% | 18 of 33 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
AstraZeneca and its competitors
Prescription medicines are the core of the business, covering the discovery, development, manufacture and commercialization of drugs. The portfolio spans oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and immune therapies, and treatments for rare diseases, with products such as Tagrisso, Enhertu, Farxiga, Fasenra and Beyfortus. Physicians in primary and specialty care are served through distributors and local representative offices in the United Kingdom, the United States, the rest of Europe, Asia, Africa and Australasia.
- Headquarters
- Cambridge, United Kingdom
- Employees
- 96,100
- Founded
- 1992
- Chief executive
- Pascal Claude Soriot
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| AstraZenecaAZN | $287.12B | 25.8% | 26.6 | +1.25% |
| NovartisNOVN | $305.16B | 34.0% | 32.6 | +14.23% |
| Roche HoldingROP | $387.48B | 33.1% | 26.7 | +25.84% |
| Novo NordiskNOVO.B | $184.87B | 50.8% | 11.2 | −7.92% |
| SanofiSAN | $116.52B | 22.3% | 25.5 | +17.04% |
| GSKGSK | $102.04B | 30.5% | 18.0 | +0.35% |
Same industry or related industries, similar size. Compare AstraZeneca with its competitors · Full profile
